When your cherished distributor fails to meet sales targets, you may be inclined to end the relationship and swiftly move to a new distributer. Only if things were so simple. Tribulations related to distributor fallout are a common problem confronted by most medical device companies.
We recently had a large multi-national company approach us with a similar quandary. They anticipated cutting business ties with their current distributor in Asia, but feared it may be adversarial. Prior to implementing this decision, they wanted to understand all the potential risks and options.
There were innumerable questions running through client’s mind.
- Is license transfer allowed?
- Are new registrations the only option? How long would that take? Does TFDA have an abbreviated pathway for products that are already approved?
- Can we continue to sell our products in the interim?
- Will we lose our current contracts with the hospitals?
- Will we need approval from our current distributor to perform transfers or new registrations?
With tens of products on the line, the client urgently needed to establish a robust, validated strategy. There was no room for errors or misguidance.
Rather than taking the risky approach of relying on a single consultant for advice, the client utilized RegDesk’s novel expert-sourced intelligence solution. A flash team of local experts in Asia with previous experience dealing with adversarial distributor relationships provided insights into best practices to remediation, with least impact on distribution and sales of the products.
The client gained tips on how to leverage Certificate of Free Sales (CFS) to get their products back onto the market, fast.
Client obtained the insights within 2 weeks rather than months with a traditional consulting company.
An increasing number of medical device companies now rely on RegDesk for reliable and fast intelligence.